ERBB2 and non-small cell lung carcinoma: T-DXd received approval in male patients for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (phase II DESTINY-Gastric01 trial; Shitara et al., 2020) and pretreated metastatic HER2-mutant non-small cell lung cancer (NSCLC) (phase II DESTINY-Lung01 trial (Li et al., 2022), phase II DESTINY-Lung02 trial (Goto et al., 2023)).